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Background
The narrow spectrum of HIV-specific neutralizing anti-
bodies points to the need for new immunogens based on
highly conserved epitopes. HIV-1 infects host cells by
membrane fusion: during this process conserved epitopes
are exposed on the viral glycoprotein gp120/41 that may
be used as targets for the induction of antibodies against
HIV-1. Neutralizing antibodies against different heterolo-
gous HIV-1 isolates may be obtained by immunizing mice
with fusion complexes on which conserved epitopes have
been stabilized by fixation, or with gp120/41s with a
CD4-independent phenotype on which these conserved
epitopes may be already exposed.
Methods
Fusion complexes were prepared using cells expressing
gp120/41 cocultivated with cells expressing the receptors
CD4-CCR5 at different temperatures, corresponding to
intermediate stages of the membrane fusion process, and
stabilized using different fixatives. Mice were immunized
to reveal the induction of HIV neutralizing antibodies and
their spleen cells used to generate hybridoma clones to be
tested for the production of neutralizing monoclonal anti-
bodies. In addition, syngeneic balb/c mouse cells express-
ing gp120/41 with a CD4-independent phenotype have
been prepared by transfection and using viral vectors and
are being used to assess their capability to induce broad
spectrum neutralizing antibodies.
Results
Results obtained indicate that: 1) fusion complexes were
immunogenic and induced neutralizing antibodies
against R5 and X4 HIV-1 heterologous isolates; 2) exten-
sive purification of antibodies allowed the removal of any
aspecific cytotoxic effect; 3) complexes prepared at higher
temperatures were more immunogenic and induced
higher titers of neutralizing antibodies; 4) titer of neutral-
izing antibodies was not affected by the fixative used; 5)
neutralizing activity was retained after CD4-CCR5 anti-
body removal; 6) CD4-independent gp120s were
expressed in syngeneic mice cells and recognized by HIV-
1 positive human sera; mice immunizations are currently
ongoing.
Conclusion
Results show that fusion complexes are immunogenic and
induce neutralizing antibodies against heterologous HIV-
1 isolates. Removal of non-specific inhibitors that con-
fused early promising results is necessary to obtain a spe-
cific antibody response. The production and selection of
neutralizing monoclonal antibodies will be useful to
identify specific immunogenic structures and epitopes to
be used to induce neutralizing antibodies when adminis-
tered in a suitable delivery system. Antibodies obtained by
immunizing with CD4-independent gp120s and anti-
body fragments isolated through phage display libraries
panning will be evaluated for their broad-spectrum neu-
tralizing activity against different HIV-1 isolates with and
without the addition of sCD4 or CD4-like antibodies.
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